This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Bristol Myers Squibb Initiates Phase...
Tech clinical trial

Bristol Myers Squibb Initiates Phase 1 for BMS-986506

Analysis based on 9 articles · First reported Mar 19, 2026 · Last updated Mar 19, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The initiation of this Phase 1 clinical trial for BMS-986506 by Bristol Myers Squibb, and the associated milestone payment to Evotec, is expected to positively impact the stock prices of both companies. It signals progress in developing novel treatments for clear cell renal cell carcinoma, potentially opening new market opportunities in oncology.

Biotechnology Pharmaceuticals Oncology
Event Summary

Bristol Myers Squibb has initiated a Phase 1 clinical study for BMS-986506, a novel CELMoD agent, for the treatment of advanced clear cell renal cell carcinoma. This marks a significant milestone in the strategic protein degradation collaboration between Bristol Myers Squibb and Evotec, which began in 2018 and expanded in 2022. Evotec will receive a $10 million milestone payment as a result of this clinical progression. The drug candidate, a 'molecular glue', was jointly developed using Evotec's PanOmics and PanHunter platforms, which combine high-performance multi-omics screening with AI-enabled data analytics and drug design capabilities. This event highlights the potential of molecular glue degraders to address previously undruggable disease-causing proteins and reshape future standards of care in oncology and beyond.

Key Actions
95 Bristol Myers Squibb initiated Phase 1 clinical study for BMS-986506
85 Evotec received $10 million milestone payment Bristol Myers Squibb
Entities Involved
stock
Evotec
Evotec will receive a $10 million milestone payment due to the initiation of the Phase 1 clinical study for BMS-986506. This validates Evotec's drug discovery platform and its strategic collaboration with Bristol Myers Squibb.
Importance 90 Sentiment 70
stock
Bristol Myers Squibb
Bristol Myers Squibb has initiated a Phase 1 clinical study for BMS-986506, a CELMoD agent, for clear cell renal cell carcinoma. This marks a significant advancement in its strategic protein degradation collaboration with Evotec.
Importance 90 Sentiment 60
per
Cord Dohrmann
Cord Dohrmann, Chief Scientific Officer of Evotec, commented on the systematic approach to discovering molecular glues and the potential of this collaboration to address unmet medical needs in oncology and beyond.
Importance 20 Sentiment 0
subs
Bristol Myers Squibb===Celgene
Evotec initially entered the long-term strategic drug discovery and development collaboration in the field of molecular glues with Bristol Myers Squibb===Celgene, which is now Bristol Myers Squibb.
Importance 10 Sentiment 0
Relationships
Evotec related ↔ Bristol Myers Squibb
Cord Dohrmann related ↔ Evotec
Bristol Myers Squibb===Celgene related ↔ Bristol Myers Squibb
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.